Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644117 | 0.92 | MAPT (0.44) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL20395893 | 0.89 | MAPT (0.44) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL6342936 | 0.89 | GAA (0.41) | ADRB2ADRB1ADRB3SMN1; SMN2MAPT | |
| Hydrogen Sulfide SCHEMBL20395882 | 0.88 | MAPT (0.43) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL2527989 | 0.87 | CREBBP (0.41) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL2525888 | 0.87 | FFAR1 (0.45) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL28845206 | 0.86 | GAA (0.41) | ADRB2ADRB1ADRB3SMN1; SMN2MAPT | |
| SCHEMBL5228091 | 0.85 | ADRB2 (0.40) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL644523 | 0.85 | CA1 (0.43) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 | |
| SCHEMBL4878299 | 0.84 | KAT6A (0.51) | ADRB2ADRB1ADRB3BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| CN-1853630-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2006-11-01 | — | — | CN | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ADRB2 460/4885ADRB1 469/4885ADRB3 575/4885 |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | ADRB2 1871/4885ADRB1 3273/4885ADRB3 2252/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ADRB2 460/4885ADRB1 469/4885ADRB3 575/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ADRB2 460/4885ADRB1 469/4885ADRB3 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.